Chemical Information
Antiviral agent ID	DrugRepV_4383
Antiviral agent name	N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide
IUPAC Name	N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide
SMILES (canonical)	C1CN(CCN1C2=CC=CC=C2)C(=O)C(CC3=CC=CC=C3)NC(=O)C4=CC=CC=C4
Molecular Formula	C26H27N3O2
Molecular Weight (g/mol)	413.5
InChl	InChI=1S/C26H27N3O2/c30-25(22-12-6-2-7-13-22)27-24(20-21-10-4-1-5-11-21)26(31)29-18-16-28(17-19-29)23-14-8-3-9-15-23/h1-15,24H,16-20H2,(H,27,30)
Structural Information
Clinical Information
Biological Information
Secondary Indication	Hendra virus (HeV) NA F0, amino acids 105 to 114
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	293FT
Secondary Indication (Viral titer)	1 μM
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	40 μM
Secondary Indication (Cell based assay)	CatL-Peptide cleavage
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Percentage inhibition [ 0.34 % ]
Reference	Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS..Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay..J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5. PubMed Central PMCID: P PMID:24501399
Comment	A novel broad-spectrum small molecule that could block cathepsin L-mediated cleavage was identified and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-CoV or Ebola, Hendra, or Nipah virus. The small molecule can be further optimized and developed into a potent broad-spectrum antiviral drug.